India has approved a wider trade margin cap for non-scheduled cancer medicines, a move that could cut prices by up to 70%. The decision was reported on October 9. The trade margin is the markup added between the manufacturer and the patient.

Capping it limits how much distributors and retailers can add to the base price of a drug. For families facing steep cancer treatment bills, the savings could be life-changing.

The final drug list and a notification from the National Pharmaceutical Pricing Authority will determine how the policy works in practice. Patients should check which medicines are covered once the list is published.

The actual savings will depend on the medicines included and how strictly the cap is enforced. Price controls only help if chemists and hospitals follow them.

India has used price controls before to make essential medicines affordable. The test, as always, will be implementation on the ground.